Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone

Trial Profile

Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Cixutumumab (Primary) ; Mitotane
  • Indications Adrenal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Nov 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Planned end date changed from 1 Apr 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top